Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 2,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $25.33, for a total value of $50,660.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.27, for a total value of $103,147.50.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.54, for a total value of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $26.68, for a total value of $140,070.00.
• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.07, for a total value of $75,210.00.

Enliven Therapeutics Stock Up 1.8 %

Shares of Enliven Therapeutics stock traded up $0.46 during trading on Tuesday, hitting $26.00. 849,423 shares of the stock traded hands, compared to its average volume of 257,450. The firm’s fifty day moving average is $23.14 and its 200-day moving average is $21.71. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $27.67. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -14.14 and a beta of 1.09.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. On average, analysts forecast that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Institutional Trading of Enliven Therapeutics

Several institutional investors have recently made changes to their positions in the business. Quest Partners LLC lifted its stake in shares of Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Enliven Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares during the period. EntryPoint Capital LLC purchased a new position in Enliven Therapeutics during the 1st quarter worth $167,000. The Manufacturers Life Insurance Company purchased a new position in shares of Enliven Therapeutics in the 2nd quarter valued at $322,000. Finally, Blackstone Inc. purchased a new position in shares of Enliven Therapeutics in the 1st quarter valued at $443,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ELVN. Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday. Finally, Robert W. Baird began coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective on the stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.